The Journal of Pediatrics
Volume 150, Issue 3 , Pages 262-267.e1 , March 2007

Characteristics of Children Receiving Proton Pump Inhibitors Continuously for Up to 11 Years Duration

  • Eric Hassall, MBChB, FRCPC

      Affiliations

    • Division of Gastroenterology, BC Children’s Hospital/University of British Columbia, Vancouver, BC, Canada
    • Corresponding Author InformationReprint requests: Eric Hassall, MD, Division of Gastroenterology, BC Children’s Hospital, 4480 Oak St, Vancouver, BC V6H 3V4, Canada.
    • ,
  • Wendy Kerr, RN, BSN

      Affiliations

    • Division of Gastroenterology, BC Children’s Hospital/University of British Columbia, Vancouver, BC, Canada
    • ,
  • Hashem B. El-Serag, MD, MPH

      Affiliations

    • Gastroenterology and Health Services Research Sections, Houston Department of Veterans Affairs Medical Center and Baylor College of Medicine, Houston, TX.

Received 30 March 2006 ,Revised 5 July 2006 ,Accepted 12 August 2006.

References 

  1. Hassall E. Outcomes of fundoplication: causes for concern, newer options. Arch Dis Child. 2005;90:1047–1052
  2. Marks RD, Richter JE, Rizzo J, Koehler RE, Spenney JG, Mills TP, et al. Omeprazole versus H2-receptor antagonists in treating patients with peptic stricture and esophagitis. Gastroenterology. 1994;106:907–915
  3. Wang WH, Huang JQ, Zheng GF, Xia HH, Wong WM, Lam SK, et al. Head-to-head comparison of H2-receptor antagonists and proton pump inhibitors in the treatment of erosive esophagitis: a meta-analysis. World J Gastroenterol. 2005;11:4067–4077
  4. Huang JQ, Hunt RH. pH, healing rate, and symptom relief in patients with GERD. Yale J Biol Med. 1999;72:181–194
  5. Hyman PE, Garvey TQ, Abrams CE. Tolerance to intravenous ranitidine. J Pediatr. 1987;110:794–796
  6. Hyman P, Hassall E. Marked basal gastric acid hypersecretion and peptic ulcer disease: medical management with combination H2-histamine receptor antagonist and anticholinergic. J Pediatr Gastroenterol Nutr. 1988;7:57–63
  7. Nwokolo CU, Smith JT, Gavey C, Sawyer A, Pounder RE. Tolerance during 29 days of conventional dosing with cimetidine, nizatidine, famotidine or ranitidine. Aliment Pharmacol Ther. 1990;4(suppl 1):29–45
  8. Wilder-Smith CH, Ernst T, Gennoni M, Zeyen B, Halter F, Merki HS. Tolerance to H2-receptor antagonists. Dig Dis Sci. 1990;35:976–983
  9. Gunasekaran TS, Hassall E. Efficacy and safety of omeprazole for severe gastroesophageal reflux in children. J Pediatr. 1993;123:148–154
  10. Hassall E, Israel DM, Shepherd R, Radke M, Dalväg A, Sköld B International Pediatric Omeprazole Study Group. Omeprazole for treatment of chronic erosive esophagitis in children: a multicenter study of efficacy, safety, tolerability and dose requirements. J Pediatr. 2000;137:800–807
  11. Tolia V, Ferry G, Gunasekaran T, Huang B, Keith R, Book L. Efficacy of lansoprazole in the treatment of gastroesophageal reflux disease in children. J Pediatr Gastroenterol Nutr. 2002;35:S308–S318
  12. Gunasekaran T, Gupta S, Gremse D, Karol M, Pan W-J, Chiu Y-L, et al. Lansoprazole in adolescents with gastroesophageal reflux disease: pharmacokinetics, pharmacodynamics, symptom relief efficacy and tolerability. J Pediatric Gastroenterol Nutr. 2002;35(suppl 4):S327–S335
  13. Fiedorek S, Tolia V, Huang B, Stolle J, Lee C, Gremse D. Efficacy and safety of lansoprazole in adolescents with gastroesophageal reflux disease. J Pediatric Gastroenterol Nutr. 2005;40:319–327
  14. Klinkenberg-Knol EC, Nelis F, Dent J, Snel P, Mitchell B, Prichard P, et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology. 2000;118:661–669
  15. Hassall E International Pediatric Omeprazole Study Group. Omeprazole for maintenance therapy of erosive esophagitis in children. [abstract] Gastroenterology. 2000;118:A658
  16. Raghunath AS, O’Morain C, McLoughlin RC. The long-term use of proton-pump inhibitors. Aliment Pharmacol Ther. 2005;22(suppl):55–63
  17. Vandenplas Y, Hassall E. Mechanisms of gastroesophageal reflux and gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr. 2002;35:119–136
  18. Hassall E. Co-morbidities in childhood Barrett’s esophagus. J Pediatr Gastroenterol Nutr. 1997;25:255–260
  19. Hassall E. Mistaking ‘life’ (as we know it) for ‘disease’. [letter] Am J Gastroenterol. 2006;101:2434–2435
  20. Kassem NY, Groen JJ, Fraenkel M. Spinal deformities and oesophageal hiatus hernia. Lancet. 1965;49:887–889
  21. Darling DB, Fisher JH, Gellis SS. Hiatal hernia and gastroesophageal reflux in infants and children: analysis of the incidence in North American children. Pediatrics. 1974;54:450–455
  22. El-Serag HB, Bailey NR, Gilger M, Rabeneck L. Endoscopic manifestations of gastroesophageal reflux disease in patients between 18 months and 25 years without neurological deficits. Am J Gastroenterol. 2002;97:1635–1639

 Supported by a grant from AstraZeneca Canada to the University of British Columbia. Dr. El-Serag is a VA HSR&D awardee (RCD 00-013-2). The study sponsor played no role in data collection, data processing, or writing of the report, or in the decision to submit the paper. The first and third authors collaborated in the writing of the first draft of the manuscript, with input from the second author. None of the authors received any payment for producing the manuscript.

PII: S0022-3476(06)01190-5

doi: 10.1016/j.jpeds.2006.08.078

The Journal of Pediatrics
Volume 150, Issue 3 , Pages 262-267.e1 , March 2007

Article Tools